FY2026 Earnings Estimate for VYGR Issued By Leerink Partnrs

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Leerink Partnrs lowered their FY2026 earnings per share estimates for shares of Voyager Therapeutics in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will earn ($0.62) per share for the year, down from their prior estimate of ($0.49). The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ FY2027 earnings at ($1.36) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the business earned $1.25 earnings per share.

A number of other equities research analysts have also recently weighed in on VYGR. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $13.97.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.16 on Friday. The company has a market capitalization of $174.45 million, a PE ratio of 4.45 and a beta of 1.02. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The firm has a 50 day moving average price of $3.76 and a 200 day moving average price of $5.32.

Insider Buying and Selling

In other news, CEO Alfred Sandrock sold 10,885 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in Voyager Therapeutics during the 4th quarter worth about $29,000. Tower Research Capital LLC TRC lifted its stake in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management boosted its holdings in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares in the last quarter. Oxford Asset Management LLP purchased a new position in Voyager Therapeutics in the fourth quarter valued at approximately $60,000. Finally, Tema Etfs LLC acquired a new stake in Voyager Therapeutics during the fourth quarter worth approximately $85,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.